Please assess the completion status of the following clinical trial:

Trial Title: Alvocidib Biomarker-driven Phase 2 AML Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be between the ages of ≥18 and ≤65 years~2. Have an established, pathologically confirmed diagnoses of AML by World Health Organization (WHO) criteria excluding acute promyelocytic leukemia (APL-M3) with a bone marrow of \>5% blasts based on histology or flow cytometry~3. Be in first relapse (within 24 months of CR) or have failed induction therapy\* (no CR or CRi after treatment with an intensive regimen (eg, anthracycline/cytarabine ± etoposide, gemtuzumab ozogamicin, or cladribine).~   \*Induction therapy may involve 1 or 2 cycles of the same regimen. Efficacy assessment of induction therapy must be \>21 days from the start of the previous induction cycle.~4. Demonstrate MCL-1 dependence of ≥30% by mitochondrial profiling in bone marrow.~5. Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2~6. Have a serum creatinine level ≤1.8 mg/dL~7. Have an alanine aminotransferase (ALT)/aspartate aminotransferase (AST) level ≤5 times upper limit of normal (ULN)~8. Have a total bilirubin level ≤2.0 mg/dL (unless secondary to Gilbert syndrome, hemolysis, or leukemia)~9. Have a left ventricular ejection fraction (LVEF) \>45% by echocardiogram (ECHO) or multigated acquisition (MUGA) scan~10. Be nonfertile or agree to use an adequate method of contraception. Sexually active patients and their partners must use an effective method of contraception associated with a low failure rate during and for at least 6 months after completion of study therapy.~11. Be able to comply with the requirements of the entire study.~12. Provide written informed consent prior to any study related procedure.~Exclusion Criteria:~1. Received more than 2 cycles of induction therapy for AML. Investigational agents as part of front-line therapy for AML may by acceptable following discussion with the Medical Monitor. Hydroxyurea is permitted (see #5 below).~2. Received any previous treatment with alvocidib or any other CDK inhibitor~3. Received a hematopoietic stem cell transplant within the previous 2 months~4. Have clinically significant graft versus host disease (GVHD), or GVHD requiring initiation or escalation of treatment within the last 21 days~5. Require concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within 12 hours) of starting treatment on either arm.~6. Received \>360 mg/m2 equivalents of daunorubicin~7. Have a peripheral blast count of \>30,000/mm3 (may use hydroxyurea as in #5 above)~8. Received antileukemic therapy within the last 3 weeks (with the exception of hydroxyurea or if the patient has definite refractory disease). Refractory patients who received therapy within the last 3 weeks may be eligible with prior approval of the Medical Monitor.~9. Diagnosed with acute promyelocytic leukemia (APL, M3)~10. Have active central nervous system (CNS) leukemia~11. Have evidence of uncontrolled disseminated intravascular coagulation~12. Have an active, uncontrolled infection~13. Have other life-threatening illness~14. Have other active malignancies or diagnosed with other malignancies within the last 6 months, except nonmelanoma skin cancer or cervical intraepithelial neoplasia~15. Have mental deficits and/or psychiatric history that may compromise the ability to give written informed consent or to comply with the study protocol.~16. Are pregnant and/or nursing~17. Have received any live vaccine within 14 days prior to first study drug administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ACM (Stage 1 / Stage 2) (Type: EXPERIMENTAL): A: alvocidib, 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
- CM (Stage 2) (Type: ACTIVE_COMPARATOR): C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 1-3; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine

Based on this trial design, predict the completion outcome and termination type (if applicable).